Ivana Magovčević-Liebisch, Vigil Neuroscience CEO
January 13, 2022 07:15 AM EST
Financing

Vig­il Neu­ro­science hits Wall Street with two ex-Am­gen TREM2 ag­o­nists

Nicole DeFeudis

Editor

Big Phar­ma large­ly aban­doned neu­ro­science over the last sev­er­al years — but the folks at Vig­il Neu­ro­science be­lieve a re­nais­sance is around the cor­ner, and ap­par­ent­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times